Exempt Chemical Preparations Under the Controlled Substances Act

DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-372] Exempt Chemical Preparations Under the Controlled Substances Act AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Exemption orders with opportunity for comment. SUMMARY: The applications for exempt chemical preparations received by the Drug Enforcement Administration between September 1, 2024, and December 31, 2025, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through December 31, 2025, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published. DATES: Comments must be submitted electronically or postmarked on or before May 19, 2026. ADDRESSES: Interested persons may file written comments on this order in accordance with 21 CFR 1308.23(e). The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. To ensure proper handling of comments, please reference “Docket No. DEA-372” on all correspondence, including any attachments. • Electronic comments: The Drug Enforcement Administration (DEA) encourages that all comments be submitted through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or to attach a file for lengthier comments. Please go to http://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon completion of your submission, you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on Regulations.gov. If you have received a comment tracking number, your comment has been successfully submitted and there is no need to resubmit the same comment. • Paper comments: Paper comments that duplicate the electronic submission are not necessary and are discouraged. Should you wish to mail a comment in lieu of an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. • Paperwork Reduction Act Comments: All comments concerning collections of information under the Paperwork Reduction Act must be submitted to the Office of Information and Regulatory Affairs, OMB, Attention: Desk Officer for DOJ, Washington, DC 20503. Please state that your comment refers to Docket No. DEA-1189. FOR FURTHER INFORMATION CONTACT: Terrence L. Boos, Ph.D., Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (571) 362-8201. SUPPLEMENTARY INFORMATION: Posting of Public Comments Please note that all comments received in response to this docket are considered part of the public record. The Drug Enforcement Administration (DEA) will make comments available for public inspection online at http://www.regulations.gov. Such information includes personal or business identifiers (such as name, address, state or Federal identifiers, etc.) voluntarily submitted by the commenter. Generally, all information voluntarily submitted by the commenter, unless clearly marked as Confidential Information in the method described below, will be publicly posted. Comments may be submitted anonymously. The Freedom of Information Act applies to all comments received. Commenters submitting comments which include personal identifying information (PII), confidential, or proprietary business information that the commenter does not want made publicly available should submit two copies of the comment. One copy must be marked “CONTAINS CONFIDENTIAL INFORMATION” and should clearly identify all PII or business information the commenter does not want to be made publicly available, including any supplemental materials. DEA will review this copy, including the claimed PII and confidential business information, in its consideration of comments. The second copy should be marked “TO BE PUBLICLY POSTED” and must have all claimed confidential PII and business information already redacted. DEA will post only the redacted comment on http://www.regulations.gov for public inspection. For easy reference, an electronic copy of this document and supplemental information to this proposed scheduling action are available at http://www.regulations.gov. Legal Authority Section 201 of the Controlled Substances Act (CSA) (21 U.S.C. 811) authorizes the Attorney General, by regulation, to exempt from certain provisions of the CSA certain compounds, mixtures, or preparations containing a controlled substance, if she finds that such compounds, mixtures, or preparations meet the requirements detailed in 21 U.S.C. 811(g)(3)(B). 1 DEA regulations at 21 CFR 1308.23 and 1308.24 further detail the criteria by which the DEA Assistant Administrator may exempt a chemical preparation or mixture from certain provisions of the CSA. The Assistant Administrator may, pursuant to 21 CFR 1308.23(f), modify or revoke the criteria by which exemptions are granted and modify the scope of exemptions at any time. 1 This authority has been delegated from the Attorney General to the DEA Administrator by 28 CFR 0.100, and subsequently redelegated to the Deputy Assistant Administrator pursuant to 28 CFR 0.104 and Section 7 of the appendix to subpart R of part 0. Exempt Chemical Preparation Applications Submitted Between September 1, 2024, and December 31, 2025 DEA received applications between September 1, 2024, and December 31, 2025, requesting exempt chemical preparation status detailed in 21 CFR 1308.23. This publication addresses preparations through December 31, 2025, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published. Pursuant to the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23, the Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart I below is intended for laboratory, industrial, educational, or special research purposes and not for general administration to a human being or animal and either: (1) contains no narcotic controlled substance and is packaged in such a form or concentration that the packaged quantity does not present any significant potential for abuse; or (2) contains either a narcotic or non-narcotic controlled substance and one or more adulterating or denaturing agents in such a manner, combination, quantity, proportion, or concentration that the preparation or mixture does not present any potential for abuse and, if the preparation or mixture contains a narcotic controlled substance, is formulated in such a manner that it incorporates methods of denaturing or other means so that the preparation or mixture is not liable to be abused or have ill effects, if abused, and so that the narcotic substance cannot in practice be removed. Accordingly, pursuant to 21 U.S.C. 811(g)(3)(B), 21 CFR 1308.23, and 21 CFR 1308.24, the Assistant Administrator has determined that each of the chemical preparations or mixtures generally described in Chart I below and specifically described in the application materials received by DEA is exempt, to the extent described in 21 CFR 1308.24, from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 (21 U.S.C. 822-823, 825-829, and 952-954) of the CSA, and 21 CFR 1301.74, as of the date that was provided in the approval letters to the individual requesters. Scope of Approval The exemptions are applicable only to the precise preparation or mixture described in the application submitted to DEA in the form(s) listed in this order and only for those above-mentioned sections of the CSA and the CFR. In accordance with 21 CFR 1308.24(h), any change in the quantitative or qualitative composition of the preparation or mixture, or change in the trade name or other designation of the preparation or mixture after the date of application requires a new application. The requirements set forth in 21 CFR 1308.24(b)-(e) apply to the exempted materials. In accordance with 21 CFR 1308.24(g), DEA may prescribe requirements other than those set forth in 21 CFR 1308.24(b)-(e) on a case-by-case basis for materials exempted in bulk quantities. Accordingly, in order to limit opportunities for diversion from the larger bulk quantities, DEA has determined that each of the exempted bulk products listed in this order may only be used in-house by the manufacturer, and may not be distributed for any purpose, or transported to other facilities. Additional exempt chemical preparation requests received between September 1, 2024, and December 31, 2025, and not otherwise referenced in this order or in prior orders, may remain under consideration until DEA receives additional information required, pursuant to 21 CFR 1308.23(d), as detailed in separate correspondence to individual requesters. DEA's order on such requests will be communicated to the public in a future Federal Register publication. DEA also notes that these exemptions are limited to exemption from only those sections of the CSA and the CFR that are specifically identified in 21 CFR 1308.24(a). All other requirements of the CSA and the CFR apply, including registration as an importer as required by 21 U.S.C. 957. Chart I Supplier name Product name Form Application date Absolute Standards, Inc Amobarbital, 100 ug/mL, in Methanol Glass ampoule: 1 ml 10/15/2025 Absolute Standards, Inc Butabarbital, 100 ug/mL, in Methanol Glass ampoule: 1 ml 10/15/2025 Absolute Standards, Inc Carisoprodol PT, 1-1000 ug/mL, in Methanol Glass ampoule: 1 ml 10/15/2025 Absolute Standards, Inc Ethylmorphine, 100 ug/mL, in Methanol Glass ampoule: 1 ml 10/15/2025 Absolute Standards, Inc Hexobarbital, 100 ug/mL, in Methanol Glass ampoule: 1 ml 10/15/2025 Absolute Standards, Inc Lysergic acid diethylamide (LSD) PT, 1-50 ug/mL, in Acetonitrile Glass ampoule: 1 ml 10/15/2025 Absolute Standards, Inc Lysergic acid diethylamide-D3 (LSD-D3) PT, 1-50 ug/mL, in Acetonitrile Glass ampoule: 1 ml 10/15/2025 Absolute Standards, Inc Meprobamate PT, 1-1000 ug/mL, in Methanol Glass ampoule: 1 ml 10/15/2025 Absolute Standards, Inc Methcathinone PT, 1-1000 ug/mL, in Acetonitrile Glass ampoule: 1 ml 10/15/2025 Absolute Standards, Inc Methylphenidate, 100 ug/mL, in Methanol Glass ampoule: 1 ml 10/15/2025 Absolute Standards, Inc Norbuprenorphine-D3, 100 ug/mL, in Methanol Glass ampoule: 1 ml 10/15/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCGACT-1 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCGACT-2 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCGLR-1 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCGLR-2 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCJACT-A 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCJACT-N 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCJAPTT-A 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCJAPTT-N 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCJCAPTT-A 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCJCPT-A 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCJCPT-N 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCJLR-A 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCJLR-N 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCJPT-A 15 Glass ampoules: 0.5 mL each 4/1/2025 Accriva Diagnostics, Inc DirectCHECK Whole Blood Control Catalog: DCJPT-N 15 Glass ampoules: 0.5 mL each 4/1/2025 Alfa Wassermann Diagnostic Technologies, LLC T4 Antibody/Substrate Reagent HDPE Ntrl Bottle: 12 mL 4/8/2025 American Proficiency Institute Whole Blood Control for Proficiency Testing Catalog: HCA 250-750 Glass ampoules: 0.5 mL each 7/8/2025 American Proficiency Institute Whole Blood Control for Proficiency Testing Catalog: HCP 250-750 Glass ampoules: 0.5 mL each 7/8/2025 American Proficiency Institute Whole Blood Control for Proficiency Testing Catalog: HJP 250-750 Glass ampoules: 0.5 mL each 7/8/2025 American Proficiency Institute Whole Blood Control for Proficiency Testing Catalog: HLR 250-750 Glass ampoules: 0.5 mL each 7/8/2025 American Proficiency Institute Whole Blood Control for Proficiency Testing Catalog: HPL 250-750 Glass ampoules: 0.5 mL each 7/8/2025 ARK Diagnostics, Inc ARK TM Ketamine II Calibrator (Kit Reference Number 5083-0002-00) Kit: 5 Dropper Vials, 10 mL each 5/1/2025 ARK Diagnostics, Inc ARK TM Ketamine II Calibrator B (Cutoff) (Kit Reference Number 5083-0002-02) Kit: 2 Dropper Vials, 10 mL each 5/1/2025 ARK Diagnostics, Inc ARK TM Ketamine II Calibrator B (Cutoff), Forensic (Kit Reference Number 5083-0005-02) Kit: 2 Dropper Vials, 10 mL each 5/1/2025 ARK Diagnostics, Inc ARK TM Ketamine II Calibrator C (Cutoff) (Kit Reference Number 5083-0002-03) Kit: 2 Dropper Vials, 10 mL each 5/1/2025 ARK Diagnostics, Inc ARK TM Ketamine II Calibrator C (Cutoff), Forensic (Kit Reference Number 5083-0005-03) Kit: 2 Dropper Vials, 10 mL each 5/1/2025 ARK Diagnostics, Inc ARK TM Ketamine II Calibrator, Forensic (Kit Reference Number 5083-0005-00) Kit: 5 Dropper Vials, 10 mL each 5/1/2025 ARK Diagnostics, Inc ARK TM Ketamine II Control (Kit Reference Number 5083-0003-00) Kit: 4 Dropper Vials, 10 mL each 5/1/2025 ARK Diagnostics, Inc ARK TM Ketamine II Control (Kit Reference Number 5083-0003-01) Kit: 4 Dropper Vials, 10 mL each 5/1/2025 ARK Diagnostics, Inc ARK TM Ketamine II Control, Forensic (Kit Reference Number 5083-0006-00) Kit: 4 Dropper Vials, 10 mL each 5/1/2025 ARK Diagnostics, Inc ARK TM Ketamine II Control, Forensic (Kit Reference Number 5083-0006-01) Kit: 4 Dropper Vials, 10 mL each 5/1/2025 Audit MicroControls, Inc Control FD Assayed Chemistry Level 1 Glass Vial: 5.0 mL 5/12/2025 Audit MicroControls, Inc Control FD Assayed Chemistry Level 1 Kit: 10 glass vials, 5 mL each 5/12/2025 Audit MicroControls, Inc Control FD Assayed Chemistry Level 2 Glass Vial: 5.0 mL 5/12/2025 Audit MicroControls, Inc Control FD Assayed Chemistry Level 2 Kit: 10 glass vials, 5 mL each 5/12/2025 Audit MicroControls, Inc Control FD Assayed Chemistry Level 3 Glass Vial: 5.0 mL 5/12/2025 Audit MicroControls, Inc Control FD Assayed Chemistry Level 3 Kit: 10 glass vials, 5 mL each 5/12/2025 Audit MicroControls, Inc Linearity FD Immunoassay for Ortho Vitros Kit Kit: 5 vials, 5 mL each 9/8/2025 Audit MicroControls, Inc Linearity FD Immunoassay for Ortho Vitros Set 1 Level A Vial: 5 mL 9/8/2025 Audit MicroControls, Inc Linearity FD Immunoassay for Ortho Vitros Set 1 Level B Vial: 5 mL 9/8/2025 Audit MicroControls, Inc Linearity FD Immunoassay for Ortho Vitros Set 1 Level C Vial: 5 mL 9/8/2025 Audit MicroControls, Inc Linearity FD Immunoassay for Ortho Vitros Set 1 Level D Vial: 5 mL 9/8/2025 Audit MicroControls, Inc Linearity FD Immunoassay for Ortho Vitros Set 1 Level E Vial: 5 mL 9/8/2025 Cayman Chemical Company (±)-9-nor-9β-hydroxy Hexahydrocannabinol (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company (±)-9-nor-9β-hydroxy Hexahydrocannabinol (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company (±)-9α-hydroxy Hexahydrocannabinol (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company (±)-9α-hydroxy Hexahydrocannabinol (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company (6aR,9R)-Delta-10-Tetrahydrocannabinol Solution 1 mg/mL in Acetonitrile Glass ampule: 1 mL 7/1/2025 Cayman Chemical Company 1 mg of 2-methylmethcathinone (hydrochloride),1 mg of 3-methylmethcathinone (hydrochloride), and 1 mg of mephedrone (hydrochloride) in 1 mL of methanol Glass ampule: 1 mL 10/1/2025 Cayman Chemical Company 1 mg of Δ8-THC-C9 in 1 mL of acetonitrile Glass ampule: 1 mL 10/1/2025 Cayman Chemical Company 1 mg of Δ9-THCA-B in 1 mL of acetonitrile Glass ampule: 1 mL 10/1/2025 Cayman Chemical Company 1 mg of Δ9-THCA-B in 1 mL of methanol Glass ampule: 1 mL 10/1/2025 Cayman Chemical Company 1 mg of Δ9-THCB butanoate in 1 mL of acetonitrile Glass ampule: 1 mL 10/1/2025 Cayman Chemical Company 1 mg of Δ9-THC-C9 in 1 mL acetonitrile Glass ampule: 1 mL 10/1/2025 Cayman Chemical Company 10(S)-hydroxy-9(R)-Hexahydrocannabinol (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 10(S)-hydroxy-9(R)-Hexahydrocannabinol (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company 100 Mg of 2-methylmethcathinone (hydrochloride), 100 Mg of 3-methylmethcathinone (hydrochloride), and 100 Mg of mephedrone (hydrochloride) in 1 mL of methanol Glass ampule: 1 mL 10/1/2025 Cayman Chemical Company 100 ug of Δ9-THCA-B in 1 mL of acetonitrile Glass ampule: 1 mL 10/1/2025 Cayman Chemical Company 100 ug of Δ9-THCA-B in 1 mL of methanol Glass ampule: 1 mL 10/1/2025 Cayman Chemical Company 11-hydroxy-9(R)-Hexahydrocannabinol (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 11-hydroxy-9(R)-Hexahydrocannabinol (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company 11-hydroxy-9(S)-Hexahydrocannabinol (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 11-hydroxy-9(S)-Hexahydrocannabinol (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company 8α,9α-epoxy Hexahydrocannabinol (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 8α,9α-epoxy Hexahydrocannabinol (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company 8β,9β-epoxy Hexahydrocannabinol (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 8β,9β-epoxy Hexahydrocannabinol (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company 9(R)-Hexahydrocannabinol (CRM) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 9(R)-Hexahydrocannabinol methyl ether (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 9(R)-Hexahydrocannabinol-d9 (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 9(R)-Hexahydrocannabinol-d9 (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company 9(R)-Hexahydrocannabiphorol (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 9(R)-Hexahydrocannabiphorol methyl ether (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 9(S)-Hexahydrocannabinol (CRM) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 9(S)-Hexahydrocannabinol-d9 (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 9(S)-Hexahydrocannabinol-d9 (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company 9(S)-Hexahydrocannabiphorol (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 9(S)-Hexahydrocannabiphorol methyl ether (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 9R-Hexahydrocannabinol Solution 1 mg/mL in Acetonitrile Glass ampule: 1 mL 7/1/2025 Cayman Chemical Company 9α,10α-Epoxyhexahydrocannabinol (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 9α,10α-Epoxyhexahydrocannabinol (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company 9β,10β-epoxy Hexahydrocannabinol (exempt preparation) Glass ampule: 1.0 mL 4/29/2025 Cayman Chemical Company 9β,10β-epoxy Hexahydrocannabinol (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company Alprazolam (CRM) 1 mg/mL in methanol Glass Ampule: 0.5 mL 12/9/2025 Cayman Chemical Company Alprazolam (CRM) 500 µg/mL in methanol Glass Ampule: 1 mL 12/9/2025 Cayman Chemical Company Clonazepam (CRM) 1 mg/mL in acetonitrile Glass Ampule: 0.5 mL 12/9/2025 Cayman Chemical Company Clonazepam (CRM) 500 µg/mL in acetonitrile Glass Ampule: 1 mL 12/9/2025 Cayman Chemical Company Delta-8-Tetrahydrocannabinol Solution 1 mg/mL in Methanol Glass ampule: 1 mL 7/1/2025 Cayman Chemical Company Delta-9 Tetrahydrocannabivarinic Acid Solution 1 mg/mL in Acetonitrile Glass ampule: 1 mL 7/1/2025 Cayman Chemical Company Delta-9-Tetrahydrocannabinolic Acid Solution 1 mg/mL in Acetonitrile Glass ampule: 1 mL 7/1/2025 Cayman Chemical Company Delta-9-Tetrahydrocannabinon Solution 1 mg/mL in Methanol Glass ampule: 1 mL 7/1/2025 Cayman Chemical Company exo-Tetrahydrocannabivarin methyl ether (exempt preparation), 1 mg/ml in acetonitrile Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company exo-Tetrahydrocannabivarin methyl ether (exempt preparation), 100 μg/ml in acetonitrile Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company exo-THC methyl ether (exempt preparation), 1 mg/ml in acetonitrile Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company exo-THC methyl ether (exempt preparation), 100 μg/ml in acetonitrile Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company exo-THCP methyl ether (exempt preparation), 1 mg/ml in acetonitrile Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company exo-THCP methyl ether (exempt preparation), 100 μg/ml in acetonitrile Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company Lormetazepam (CRM), 1 mg/mL in methanol Glass ampule: 1.0 mL 9/23/2025 Cayman Chemical Company meta-Fluorofentanyl-d5 (hydrochloride) (exempt preparation) 100 μg/mL in methanol Glass vial: 1.0 mL 4/18/2025 Cayman Chemical Company meta-methyl Acetyl fentanyl (hydrochloride) (exempt preparation) 100 μg/mL in methanol Glass vial: 1.0 mL 4/18/2025 Cayman Chemical Company meta-Methylfentanyl-d5 (hydrochloride) (exempt preparation) 100 μg/mL in methanol Glass vial: 1.0 mL 4/18/2025 Cayman Chemical Company ortho-Fluorofentanyl-d5 (hydrochloride) (exempt preparation) 100 μg/mL in methanol Glass vial: 1.0 mL 4/18/2025 Cayman Chemical Company ortho-methyl Acetyl fentanyl (hydrochloride) (exempt preparation) 100 μg/mL in methanol Glass vial: 1.0 mL 4/18/2025 Cayman Chemical Company para-methyl Acetyl fentanyl (hydrochloride) (exempt preparation) 100 μg/mL in methanol Glass vial: 1.0 mL 4/18/2025 Cayman Chemical Company para-Methylfentanyl-d5 (hydrochloride) (exempt preparation) 100 μg/mL in methanol Glass vial: 1.0 mL 4/18/2025 Cayman Chemical Company Phytocannabinoid Acids Mixture 6 Solution 1 mg/mL in 99:1 acetonitrile/DIPEA stabilized with 0.05% ascorbic acid Glass ampule: 1 mL 7/1/2025 Cayman Chemical Company Phytocannabinoid Neutrals Mixture 8 Solution 1 mg/mL in Acetonitrile Glass ampule: 1 mL 7/1/2025 Cayman Chemical Company Protonitazene-d7 (CRM) (100 µg/ml Methanol) Glass vial: 1.0 8/13/2025 Cayman Chemical Company Tetrahydrocannabivarin Solution 1 mg/mL in Methanol Glass ampule: 1 mL 7/1/2025 Cayman Chemical Company α'-hydroxy Fentanyl (exempt preparation) (100 µg/ml Methanol) Glass vial: 1.0 8/13/2025 Cayman Chemical Company α-Pyrrolidinoisohexanophenone-d8 (hydrochloride) (CRM) (100 µg/ml Methanol) Glass vial: 1.0 8/13/2025 Cayman Chemical Company Δ8-THC methyl ether (exempt preparation), 1 mg/ml in acetonitrile Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company Δ8-THC-methylcarbonate (exempt preparation), 1 mg/ml in acetonitrile Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company Δ8-THCP-d3 (exempt preparation) (1 mg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company Δ8-THCP-d3 (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company Δ9-THC methyl ether (exempt preparation), 1 mg/ml in 99:1 CAN:DIPEA Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company Δ9-THC methyl ether (exempt preparation), 1 mg/ml in acetonitrile Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company Δ9-THC methyl ether (exempt preparation), 1 mg/ml in methanol Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company Δ9-THC methyl ether (exempt preparation), 100 μg/ml in 99:1 CAN:DIPEA Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company Δ9-THC-methylcarbonate (exempt preparation), 1 mg/ml in 99:1 CAN:DIPEA Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company Δ9-THC-methylcarbonate (exempt preparation), 1 mg/ml in acetonitrile Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company Δ9-THC-methylcarbonate (exempt preparation), 100 μg/ml in 99:1 CAN:DIPEA Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company Δ9-THC-methylcarbonate (exempt preparation), 100 μg/ml in acetonitrile Glass vial: 1.0 mL 4/7/2025 Cayman Chemical Company Δ9-THCP-d3 (exempt preparation) (1 mg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cayman Chemical Company Δ9-THCP-d3 (exempt preparation) (100 µg/ml Acetonitrile) Glass vial: 1.0 8/13/2025 Cerilliant Corporation 3'-fluoro ortho-Fluorofentanyl HCl: 0.1 mg/mL in 0.5 mL solvent Glass Ampule: 0.5 ml 8/13/2025 Cerilliant Corporation 3'-Fluorofentanyl HCl: 0.1 mg/mL in 0.5 mL solvent Glass Ampule: 0.5 ml 8/13/2025 Cerilliant Corporation 4-Chloromethcathionone HCl (4-CMC HCl) Glass ampule: 1 mL 12/17/2025 Cerilliant Corporation Brivaracetam: 1.0 mg/mL in 1 mL solvent Glass Ampule: 1 ml 8/13/2025 Cerilliant Corporation Cannabinoid Mixture (Neutrals) 8 Component Solution HC: 1.0 mg/mL in 0.5 mL Solvent Glass Ampule: 0.5 ml 8/13/2025 Cerilliant Corporation Cannabinoid Mixture (Acids) 6 Component Solution HC: 1.0 mg/mL in 0.5 mL Solvent Glass Ampule: 0.5 ml 8/13/2025 Cerilliant Corporation FEN Validation Sample Set 1 Set: 3 tubes, 10 ml each 7/18/2025 Cerilliant Corporation FEN Validation Sample Set 2 Set: 9 tubes, 10 ml each 7/18/2025 Cerilliant Corporation FEN Validation Sample Set 3 Set: 4 tubes, 30 ml each 7/18/2025 Cerilliant Corporation FEN Validation Sample Set 4 Set: 2 tubes,10 ml each 7/18/2025 Cerilliant Corporation FEN Validation Sample Set 5 Set: 52 vials, 1 ml each 7/18/2025 Cerilliant Corporation LC-ABZ & ABZ+BT Mix#2&3 Glass ampule: 1 mL 11/6/2025 Cerilliant Corporation meta-Fluoro acrylfetanyl HCl: 0.1 mg/mL in 1 mL solvent Glass Ampule: 1 ml 8/13/2025 Cerilliant Corporation Phenmetrazine HCl: 0.1 mg/mL in solvent Glass Ampule: 1 ml 8/13/2025 CFSAA—RTI International 12198-102-8 Glass tube: 7 ml 7/30/2025 CFSAA—RTI International 12198-102-9 Glass tube: 7 ml 7/30/2025 Chiron AS (-)-trans-Δ9-THC (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS (-)-trans-Δ9-THC-13C4 (pentyl-2,3,4,5-13C4) (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS (-)-trans-Δ9-THC-d3 (pentyl-5,5,5-d3) (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS (±)-MDA hydrochloride (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS (±)-MDA-d5 hydrochloride (alpha-methyl-d3-ethylamine-1,2-d2) (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS (±)-MDMA hydrochloride (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS (±)-Methadone hydrochloride (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS (±)-trans-11-Nor-9-carboxy-Δ9-THC-d3 (pentyl-5,5,5-d3) (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS Benzoylecgonine (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS Benzoylecgonine-d3 tetrahydrate (N-methyl-d3) (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS Cocaine hydrochloride (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS Codeine (free base) (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS Dihydrocodeine-d6 hydrochloride (N-methyl-d3, methoxy-d3 (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS DL-Amphetamine (free base) (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS DL-Methamphetamine hydrochloride (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS Morphine monohydrate (in methanol) Glass ampule: 1 mL 11/10/2025 Chiron AS Morphine-d3 hydrochloride (N-methyl-d3) (in methanol) Glass ampule: 1 mL 11/10/2025 Chromsystems Instruments and Chemicals GmbH 3PLUS1® Multilevel Plasma Calibrator Set (92025-XT2) 4 Vials: 1 mL each 7/8/2025 Chromsystems Instruments and Chemicals GmbH MassCheck® Antiepileptic Drugs XT2 Plasma Control Set Level 1 (0250-XT2) 5 Vials: 1 mL each 7/8/2025 Chromsystems Instruments and Chemicals GmbH MassCheck® Antiepileptic Drugs XT2 Plasma Control Set Level 2 (0251-XT2) 5 Vials: 1 mL each 7/8/2025 Cliniqa Corporation Multi Constituent Calibrator (MCC) Master Calibrator (or other Description) Level 1 Bottle/vial: 5 mL—2 L 4/30/2025 Cliniqa Corporation Multi Constituent Calibrator (MCC) Master Calibrator (or other Description) Level 2 Bottle/vial: 5 mL—2 L 4/30/2025 Cliniqa Corporation Multi Constituent Calibrator (MCC) Master Calibrator (or other Description) Level 3 Bottle/vial: 5 mL—2 L 4/30/2025 Cliniqa Corporation Multi Constituent Calibrator (MCC) Master Calibrator (or other Description) Level 4 Bottle/vial: 5 mL—2 L 4/30/2025 Cliniqa Corporation Multi Constituent Calibrator (MCC) Master Calibrator (or other Description) Level 5 Bottle/vial: 5 mL—2 L 4/30/2025 Cliniqa Corporation Multi Constituent Calibrator (MCC) Master Calibrator (or other Description) Level 6 Bottle/vial: 5 mL—2 L 4/30/2025 College of American Pathologists Whole Blood Control for Proficiency Testing Catalog: CT2 250-750 Glass ampoules: 0.5 mL each 7/8/2025 College of American Pathologists Whole Blood Control for Proficiency Testing Catalog: CT3 250-750 Glass ampoules: 0.5 mL each 7/8/2025 College of American Pathologists Whole Blood Control for Proficiency Testing Catalog: CT3Q 250-750 Glass ampoules: 0.5 mL each 7/8/2025 College of American Pathologists Whole Blood Control for Proficiency Testing Catalog: POC15 250-750 Glass ampoules: 0.5 mL each 7/8/2025 College of American Pathologists Whole Blood Control for Proficiency Testing Catalog: POC16 250-750 Glass ampoules: 0.5 mL each 7/8/2025 College of American Pathologists Whole Blood Control for Proficiency Testing Catalog: WP4 250-750 Glass ampoules: 0.5 mL each 7/8/2025 College of American Pathologists Whole Blood Control for Proficiency Testing Catalog: WP6 250-750 Glass ampoules: 0.5 mL each 7/8/2025 College of American Pathologists Whole Blood Control for Proficiency Testing Catalog:CT2Q 250-750 Glass ampoules: 0.5 mL each 7/8/2025 College of American Pathologists (CAP) 2026 DMPM-01 HDPE bottle: 40 ml 7/29/2025 College of American Pathologists (CAP) 2026 DMPM-02 HDPE bottle: 40 ml 7/29/2025 College of American Pathologists (CAP) 2026 DMPM-03 HDPE bottle: 40 ml 7/29/2025 College of American Pathologists (CAP) 2026 DMPM-05 HDPE bottle: 40 ml 7/29/2025 College of American Pathologists (CAP) 2026 DMPM-06 HDPE bottle: 40 ml 7/29/2025 College of American Pathologists (CAP) 2026 DMPM-07 HDPE bottle: 40 ml 7/29/2025 College of American Pathologists (CAP) 2026 FTC-03 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 FTC-04 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 FTC-06 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 FTC-07 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 FTC-08 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 FTC-10 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 FTC-11 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 FTC-12 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 FTC-13 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 FTC-14 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 FTC-15 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 NOB-01 Amber glass vial: 15 mL 7/17/2025 College of American Pathologists (CAP) 2026 NOB-02 Amber glass vial: 15 mL 7/17/2025 College of American Pathologists (CAP) 2026 NOB-03 Amber glass vial: 15 mL 7/17/2025 College of American Pathologists (CAP) 2026 NOB-04 Amber glass vial: 15 mL 7/17/2025 College of American Pathologists (CAP) 2026 NOB-05 Amber glass vial: 15 mL 7/17/2025 College of American Pathologists (CAP) 2026 NOB-06 Amber glass vial: 15 mL 7/17/2025 College of American Pathologists (CAP) 2026 OFD-01 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-02 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-03 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-04 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-05 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-06 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-07 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-08 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-09 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-10 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-11 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-12 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-13 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-14 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-15 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-16 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-17 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-18 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-19 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 OFD-20 HDPE vial: 2 ml 7/29/2025 College of American Pathologists (CAP) 2026 SCDD-01 HDPE bottle: 10 mL 7/17/2025 College of American Pathologists (CAP) 2026 SCDD-02 HDPE bottle: 10 mL 7/17/2025 College of American Pathologists (CAP) 2026 SCDD-03 HDPE bottle: 10 mL 7/17/2025 College of American Pathologists (CAP) 2026 SCDD-04 HDPE bottle: 10 mL 7/17/2025 College of American Pathologists (CAP) 2026 SCDD-06 HDPE bottle: 10 mL 7/17/2025 College of American Pathologists (CAP) 2026 T-01 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 T-02 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 T-03 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 T-07 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 T-09 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 T-10 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 T-12 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 T-14 HDPE bottle: 20 ml 7/29/2025 College of American Pathologists (CAP) 2026 T-15 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 THCB-01 Glass vial: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 THCB-02 Glass vial: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 THCB-03 Glass vial: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 THCB-04 Glass vial: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 THCB-05 Glass vial: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 THCB-06 Glass vial: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-01 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-02 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-03 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-04 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-05 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-06 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-07 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-08 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-09 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-10 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-11 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-12 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-13 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-14 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UDS-15 HDPE bottle: 10 ml 7/29/2025 College of American Pathologists (CAP) 2026 UT-01 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 UT-02 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 UT-05 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 UT-06 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 UT-07 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 UT-09 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 UT-11 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 UT-12 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 UT-13 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 UT-15 HDPE bottle: 50 ml 7/29/2025 College of American Pathologists (CAP) 2026 UTCO-01 HDPE bottle: 40 ml 7/29/2025 College of American Pathologists (CAP) 2026 ZE-01 Glass vial: 5 ml 7/29/2025 College of American Pathologists (CAP) 2026 ZE-02 Glass vial: 5 ml 7/29/2025 College of American Pathologists (CAP) 2026 ZE-03 Glass vial: 5 ml 7/29/2025 College of American Pathologists (CAP) 2026 ZE-04 Glass vial: 5 ml 7/29/2025 College of American Pathologists (CAP) 2026 ZE-05 Glass vial: 5 ml 7/29/2025 College of American Pathologists (CAP) 2026 ZE-06 Glass vial: 5 ml 7/29/2025 Helena Laboratories SPIFE Nexus Alkaline Phosphatase (ALP) Kit, Cat. No. 2345, 2346 Kit: 10 gels 4/29/2025 LGC—Dr. Ehrenstorfer Custom 1-Methylamino-1-(3,4-methylenedioxyphenyl)-propane Hydrochloride 10 ug/mL in Acetonitrile Pack: 5 ampules, 1 mL each 9/24/2025 LGC—Dr. Ehrenstorfer Custom 1-Methylamino-1-(3,4-methylenedioxyphenyl)-propane Hydrochloride 10 ug/mL in Acetonitrile Hydrochloride 10 ug/mL in Acetonitrile Amber glass ampule: 1 mL 9/24/2025 LGC—Dr. Ehrenstorfer Custom Pharmaceutical Mixture 5-17941 (100 ug/mL in Methanol) Clamshell: 3 vials, 1 mL each 9/12/2025 LGC Clinical Diagnostics, Inc Fertility 1 ab Bulk—Level 1 Volumetric glassware: 8,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 ab Bulk—Level 2 Volumetric glassware: 8,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 ab Bulk—Level 3 Volumetric glassware: 8,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 ab Bulk—Level 4 Volumetric glassware: 8,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 ab Bulk—Level 5 Volumetric glassware: 8,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 ab WrkBlk—Level 1 Volumetric glassware: 200-20,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 ab WrkBlk—Level 5 Volumetric glassware: 200-20,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 re Bulk—Level 1 Volumetric glassware: 8,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 re Bulk—Level 2 Volumetric glassware: 8,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 re Bulk—Level 3 Volumetric glassware: 8,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 re Bulk—Level 4 Volumetric glassware: 8,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 re Bulk—Level 5 Volumetric glassware: 8,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 re WrkBlk—Level 1 Volumetric glassware: 200-20,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc Fertility 1 re WrkBlk—Level 5 Volumetric glassware: 200-20,000 mL 9/5/2024 LGC Clinical Diagnostics, Inc VALIDATE Fertility 1 Test Set 502ab 5 Bottles: 3 mL each 9/5/2024 LGC Clinical Diagnostics, Inc VALIDATE Fertility 1 Test Set 502re 5 Bottles: 4 mL each 9/5/2024 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids 1003ro Bulk Level 1 Plastic/Nalgene bottles or carboys: 3,600 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids 1003ro Bulk Level 2 Plastic/Nalgene bottles or carboys: 3,600 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids 1003ro Bulk Level 3 Plastic/Nalgene bottles or carboys: 3,600 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids 1003ro Bulk Level 4 Plastic/Nalgene bottles or carboys: 3,600 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids 1003ro Bulk Level 5 Plastic/Nalgene bottles or carboys: 3,600 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids 1003ro Working Bulk Level 1 Plastic/Nalgene bottles or carboys: 9,000 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids 1003ro Working Bulk Level 5 Plastic/Nalgene bottles or carboys: 9,000 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids Level 1 Plastic dropper bottle: 6 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids Level 2 Plastic dropper bottle: 6 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids Level 3 Plastic dropper bottle: 6 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids Level 4 Plastic dropper bottle: 6 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS Steroids Level 5 Plastic dropper bottle: 6 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS TDM1 Bulk Level 1 Plastic/Nalgene bottles or carboys: 3,600 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS TDM1 Bulk Level 2 Plastic/Nalgene bottles or carboys: 3,600 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS TDM1 Bulk Level 3 Plastic/Nalgene bottles or carboys: 3,600 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS TDM1 Bulk Level 4 Plastic/Nalgene bottles or carboys: 3,600 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS TDM1 Bulk Level 5 Plastic/Nalgene bottles or carboys: 3,600 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS TDM1 Level 1 Plastic dropper bottle: 6 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS TDM1 Level 2 Plastic dropper bottle: 6 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS TDM1 Level 3 Plastic dropper bottle: 6 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS TDM1 Level 4 Plastic dropper bottle: 6 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS TDM1 Level 5 Plastic dropper bottle: 6 mL 10/24/2025 LGC Clinical Diagnostics, Inc VALIDATE LCMS TDM1 Working Bulk Level 1 Plastic/Nalgene bottles or carboys: 9,000 mL 10/24/2025 LGC Standards (-)-a-Acetylmethadol Hydrochloride (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards (-)-a-Methadol (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards (+)-19-Norandrost-4-ene-3,17-dione (1mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards (+)-Tramadol-d6 Hydrochloride (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards (R)-Ketamine Hydrochloride (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards (S)-Ketamine Hydrochloride (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards (S)-Ketamine-d6 Hydrochloride (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards (S)-Methadone Hydrochloride (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards 10-Oxo Naloxone (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards 17α-Methyl Testosterone (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards 2,3-Thioepoxy Madol (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards 3-O-(Codein-2-yl)morphine (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards 4-Hydroxy Nandrolone (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards 4-Hydroxy Testosterone (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards 5a-Androstane-3a,17b-diol (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards 5a-Dihydro Testosterone Undecanoate (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards 6-Acetyl Morphine (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards 6alpha-Oxycodol (1mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Allobarbital-d10 (1mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Alphaprodine Hydrochloride (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Amineptine (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Aminorex (1 mg/ml in Acetronitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Androstenedione-d3 (1.0 mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Anileridine (1.0 mg/mL in ethyl acetate) Glass ampoule: 1 mL 4/16/2025 LGC Standards Barbital-d5 (1.0mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Boldenone Undecylenate (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Boldenone-d3 (1.0 mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Boldione (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Buprenorphine N-oxide (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Butobarbital (1.0 mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Chlordiazepoxide (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Clobazam-13C6 (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Clonitazene (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Clorazepate Dipotassium (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Clostebol (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Clotiazepam (1 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Codeine (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Delorazepam (100 ug/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Diazepam (1mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Diethylpropion Hydrochloride (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Diethylpropion Hydrochloride (1mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Dihydrocodeine Phosphate (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Diphenoxylate Hydrochloride (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards D-threo-Methylphenidate Hydrochloride (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Ecgonidine Methyl Ester (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Ethyl Loflazepate (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Ethyl Morphine 6-b-D-Glucuronide (1.0mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Fencamfamin Hydrochloride (1 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Fentanyl-d5 (100 ug/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Fludiazepam (1 mg/mL in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Hydrocodone (1.0mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Ketamine Hydrochloride (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards L-Cocaine (1.0 mg/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Levorphanol L-Tartrate (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Loprazolam (100 ug/mL in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Lorazepam (1.0 mg/mL in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards MDPV Hydrochloride (1 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Mephedrone Hydrochloride (1.0 mg/mL in methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Mephedrone-d3 Hydrochloride (100ug/ml in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Meprobamate-d3 (100 ug/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Methandrostenolone-d3 (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Methcathinone Hydrochloride (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Methyprylon (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Metribolone (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards m-Hydroxycocaine (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Midazolam (1.0 mg/mL in methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Midazolam-d6 (1.0 mg/mL in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Morphine (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Morphine 3-b-D-Glucuronide (1.0 mg/mL in Methanol w/0.05% NaOH) Glass ampoule: 1 mL 4/16/2025 LGC Standards Morphine 6-b-D-Glucuronide (1.0 mg/mL in Water:Methanol 80:20) Glass ampoule: 1 mL 4/16/2025 LGC Standards Morphine-d3 (100 μg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Nandrolone (1.0 mg/mL in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Nandrolone-d3 (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards N-Benzylpiperazine Dihydrochloride (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Norbolethone (1.0mg/ml in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Norclostebol (1.0 mg/mL in Acetonitrile) Glass ampoule: 1 mL 4/16/2025 LGC Standards Nordazepam-d5 (1.0 mg/mL in Methanol) Glass ampoule: 1 mL 4/16/2025 LGC Standards Norhydrocodone-D3.HCl, 1mg/ml in Methanol (as free base) Glass ampule: 1 mL 8/28/2025 LG